High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells

Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):276-81. doi: 10.1161/01.ATV.0000112012.33770.2a. Epub 2003 Dec 11.

Abstract

Objective: Osteopontin is upregulated in the diabetic vascular wall and in vascular smooth muscle cells cultured under high glucose concentration. In the present study, we analyzed the mechanism of high glucose-induced upregulation of osteopontin in cultured rat aortic smooth muscle cells.

Methods and results: We found that an inhibitor of Rho-associated protein kinase, Y-27632, suppressed osteopontin mRNA expression under high glucose concentration. Transfection of cells with a constitutive active Rho mutant, pSRalpha-myc-RhoDA, enhanced osteopontin mRNA expression. Furthermore, incubation of cells under high glucose concentration activated Rho, indicating that Rho/Rho kinase pathway mediates high-glucose-stimulated osteopontin expression. Treatment of cells with an inhibitor of protein kinase C, GF109203X, and azaserine, an inhibitor of the hexosamine pathway, suppressed high glucose-induced Rho activation. Glucosamine treatment was shown to activate Rho. Treatment of cells with an inhibitor of MEK1, PD98059, suppressed osteopontin mRNA expression under high glucose concentration. Incubation of cells under high glucose concentration activated ERK. Finally, transfection of cells with pSRalpha-myc-RhoDA also activated ERK.

Conclusions: In conclusion, our present findings support a notion that Rho/Rho kinase pathway functions downstream of protein kinase C and the hexosamine pathways and upstream of ERK in mediating high-glucose-induced upregulation of osteopontin expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology
  • Animals
  • Aorta / cytology*
  • Enzyme Inhibitors / pharmacology
  • Glucose / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Indoles / pharmacology
  • Intracellular Signaling Peptides and Proteins
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / physiology
  • Male
  • Maleimides / pharmacology
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology*
  • Muscle, Smooth, Vascular / metabolism*
  • Osteopontin
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Protein Prenylation / physiology
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / metabolism*
  • Pyridines / pharmacology
  • Quinolines / pharmacology
  • Rats
  • Rats, Wistar
  • Sialoglycoproteins / metabolism*
  • Up-Regulation / physiology*
  • rho-Associated Kinases
  • rhoA GTP-Binding Protein / metabolism*

Substances

  • Amides
  • Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Intracellular Signaling Peptides and Proteins
  • Maleimides
  • Pyridines
  • Quinolines
  • Sialoglycoproteins
  • Spp1 protein, rat
  • Osteopontin
  • Y 27632
  • Protein Serine-Threonine Kinases
  • rho-Associated Kinases
  • Protein Kinase C
  • Mitogen-Activated Protein Kinases
  • rhoA GTP-Binding Protein
  • Glucose
  • bisindolylmaleimide I
  • pitavastatin